*New additions in COPD Management (GOLD 2025)* 1. *Dupilumab:* An IL-4 inhibitor has been added as a biologic when the patient is on maximum inhaler therapy but still experiences frequent exacerbations with type 2 inflammation (Eosinophilic inflammation ; Eosinophills >300) and has chronic bronchitis.